MSD has entered into a multi-year agreement with Google Cloud valued at up to $1 billion, enabling widespread deployment of advanced artificial intelligence tools across its global workforce of 75,000 employees. The collaboration will integrate Google Cloud’s agentic AI capabilities throughout the organisation, spanning research and development, manufacturing, commercial operations, and corporate functions. This move signals a significant step in the MSD Google Cloud Partnership as the pharmaceutical company expands its use of digital technologies during a critical product launch phase.
Under the arrangement, Google Cloud personnel will work alongside MSD teams to implement the platform, anchored by Gemini Enterprise, which serves as the central system for managing and deploying AI agents. The platform includes a suite of specialised tools, such as the newly introduced Deep Research capability. This tool is designed to autonomously plan and execute complex, multi-step R&D processes, combining open-source data with proprietary internal information within a unified interface. Deep Research is offered in two configurations: a standard version focused on speed and efficiency, and a Max version aimed at delivering higher-quality contextual analysis and synthesis.
The agreement provides early momentum for Google Cloud’s rollout of Gemini Enterprise, positioning it within a competitive landscape that includes offerings from NVIDIA, Alphabet/Isomorphic Labs, Anthropic, OpenAI, and Amazon. MSD’s participation also aligns with a broader group of enterprise adopters announced at Google’s Cloud Next conference in Las Vegas, including Tata Steel, PepsiCo, and GE. “Merck’s collaboration with Google Cloud represents the next phase of our AI journey, extending our longstanding use of advanced technologies into an intelligent agentic ecosystem that will work alongside our teams, as we enter one of the most significant launch periods in our company’s history,” said Dave Williams, the pharma group’s chief information and digital officer. “AI agents and generative tools will help our teams around the world reimagine processes at scale and bring scientific breakthroughs to patients faster,” he added.
From Google Cloud’s perspective, the partnership reflects a broader shift in how technology is embedded across the pharmaceutical value chain. “Our partnership with Merck represents a fundamental shift in how technology supports the entire pharma value chain,” said Thomas Kurian, chief executive of Google Cloud. “By deploying an industry-first agentic ecosystem powered by Gemini Enterprise, Merck is not just optimising business processes; it is building a future where the speed of AI and the expertise of human ingenuity come together to bring drugs to patients faster and solve problems that were previously out of reach.” Alongside this, Google Cloud announced a $750 million fund aimed at supporting consulting firms, system integrators, and software partners to expand capabilities within its AI ecosystem, further reinforcing the scope of the MSD Google Cloud Partnership.
